Accès gratuit
Numéro
Med Sci (Paris)
Volume 22, Numéro 1, Janvier 2006
Page(s) 7 - 9
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20062217
Publié en ligne 15 janvier 2006
  1. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346 : 561–4.
  2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365 ; 61–5.
  3. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258 : 1946–9.
  4. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50 : 83–90.
  5. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol : a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215 : 89–97.
  6. McAllister SD, Glass M. CB(1) and CB(2) receptor-mediated signalling : a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002; 66 : 61–171.
  7. Howlett AC, Johnson MR, Melvin LS, Milne GM. Nonclassical cannabinoid analgetics inhibit adenylate cyclase : development of a cannabinoid receptor model. Mol Pharmacol 1988; 33 : 297–302.
  8. Bouaboula M, Poinot-Chazel C, Marchand J, et al. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 1996; 237 : 704–11.
  9. Daaka Y, Zhu W, Friedman H, Klein TW. Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor. DNA Cell Biol 1997; 16 : 301–9.
  10. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor kappa B/Rel activation. Mol Pharmacol 1996; 50 : 334–41.
  11. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66 : 123–42.
  12. Klein TW, Newton C, Larsen K, et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74 : 486–96.
  13. Srivastava MD, Srivastava BI, Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998; 40 : 179–85.
  14. Yuan M, Kiertscher SM, Cheng Q, et al. Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 2002; 133 : 124–31.
  15. Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000; 97 : 9561–6.
  16. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 2000; 396 : 141–9.
  17. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434 : 782–6.
  18. Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284 : 644–50.
  19. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103 : 2805–9.
  20. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion : results of a randomised controlled trial. Pain 2004; 112 : 299–306.
  21. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17 : 21–9.
  22. Burstein SH, Audette CA, Breuer A, et al. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 1992; 35 : 3135–41.
  23. Burstein SH. Ajulemic acid (CT3) : a potent analog of the acid metabolites of THC. Curr Pharm Des 2000; 6 : 1339–45.
  24. Sumariwalla PF, Gallily R, Tchilibon S, et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum 2004; 50 : 985–98.
  25. Ibrahim MM, Porreca F, Lai J, et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005; 102 : 3093–8.
  26. Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain : pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100 : 10529–33
  27. Malan TP Jr, Ibrahim MM, Lai J, et al. CB2 cannabinoid receptor agonists : pain relief without psychoactive effects ? Curr Opin Pharmacol 2003; 3 : 62–7.
  28. Hanus L, Breuer A, Tchilibon S, et al. HU-308 : a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 1999; 96 : 14228–33.
  29. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2006 (sous presse).

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.